Halofuginone Lactate CAS#: 82186-71-8

By great_watson-int,
Identification Physical Data Spectra
Route of Synthesis (ROS) Safety and Hazards Other Data

Identification

英文名 Halofuginone Lactate
分子结构
CAS编号 82186-71-8
EINECS Number
MDL Number
Beilstein Registry Number
别名 7-Bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one 2-hydroxypropanoate
分子式 C16H17BrClN3O3 : C3H6O3
分子量 414.7 : 90.1
InChI
InChI Key
Canonical SMILES O=C1C2=CC(Cl)=C(Br)C=C2N=CN1CC(C[C@H](NCCC3)[C@@H]3O)=O.CC(O)C(O)=O

Physical Data

Appearance No data available
Solubility No data available
Flash Point No data available
Refractive index No data available
Sensitivity No data available
Melting Point No data available

Spectra

No data available

Route of Synthesis (ROS)

No data available

Safety and Hazards

No data available

Other Data

HS Code 382290
Storage At room temperature and away from light
Related Chemicals 55837-20-2 (free base)
Use Pattern
Halofuginone Lactate is chemically 7-Bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one 2-hydroxypropanoate. Halofuginone Lactate is supplied with detailed characterization data compliant with regulatory guideline. Halofuginone Lactate can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Halofuginone. The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. ChemWhat products are for analytical purpose only and not for human use.

Halofuginone CAS#: 55837-20-2

By great_watson-int,
Halofuginone CAS 55837-20-2 structure
IdentificationPhysical DataSpectra
Route of Synthesis (ROS)Safety and HazardsOther Data

Identification

英文名Halofuginone
IUPAC Name7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one
分子结构Halofuginone CAS 55837-20-2 structure
CAS编号 55837-20-2
别名7-bromo-6-chlorofebrifugine; halofuginone; halofunginone; Stenorol; 
7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one; Tempostatin; RU 19110
分子式C16H17BrClN3O3
分子量414.686
InChIInChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2/t14-,15+/m0/s1
InChI KeyLVASCWIMLIKXLA-LSDHHAIUSA-N
Canonical SMILESC1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
Isomeric SMILESC1C[C@H]([C@@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
Patent Information
Patent IDTitlePublication Date
WO2007/120606METHODS FOR MODULATING FORMATION AND PROGRESSION OF CELLULITE2007
EP1109559INHIBITION OF PATHOGENIC PROCESSES RELATED TO TISSUE TRAUMA2005
US4665100Process for formulating a synthetic drug for use in animal feed, and resulting formulation1987

Physical Data

AppearanceWhite or off-white powder
SolubilityDMSO : 9 mg/mL (21.70 mM; Need ultrasonic and warming)
Boiling Point595.8 °C at 760 mmHg
Density1.73 g/cm3
Melting Point, °C
144 – 147
160

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Frequency (NMR Spectroscopy), MHz
Chemical shifts1Hdimethylsulfoxide-d6 500
Chemical shifts 13Cdimethylsulfoxide-d6125
Chemical shifts13Cchloroform-d1125
Chemical shifts 1Hchloroform-d1500
Description (IR Spectroscopy)Solvent (IR Spectroscopy)
Bandsneat (no solvent, solid phase)

Route of Synthesis (ROS)

Route of Synthesis (ROS) of Halofuginone CAS 55837-20-2
Route of Synthesis (ROS) of Halofuginone CAS 55837-20-2
ConditionsYield
With potassium carbonate In water pH=10

Experimental Procedure
The salt (-)-32HBr was basified topH 10 with 0.1Maq. K2CO3 and extracted with DCM (5 5 mL). Thecombined organic layers were washed with brine (25 mL), driedover MgSO4, filtered, and concentrated in vacuo (without heating) to afford (-)-3 (14 mg, 93percent) as a white solid. Mp 143e145 C;{lit.,9 Mp 160 C (decomp.)}; [a]D20 5.4 (c 0.50, EtOH); {lit.,9[a]D2010 (c 0.5, DMF)}; IR (neat): 3128, 2926, 2852, 1722, 1674,1607, 1448, 1382, 1309, 1223, 1106, 1075, 1043, 900 cm1; HRMS(ESI): calcd. for [C16H1779Br35ClN3O3 H] 414.0220, found 414.0212;1H NMR ((CD3)2SO, 500 MHz): d 1.16e1.42 (m, 2H), 1.52e1.61 (m,1H), 1.84e1.95 (m, 1H), 2.32e2.40 (m, 1H), 2.45 (dd, J 15.5, 9.0 Hz,1H), 2.64 (td, J 9.0, 4.0 Hz, 1H), 2.75e2.84 (m, 1H), 2.93e3.03 (m,2H), 4.76 (d, J 6.0 Hz, 1H), 4.94e5.06 (m, 2H), 8.16 (s, 1H), 8.22 (s,1H), 8.24 (s, 1H) ppm (OH not visible by 1H NMR spectroscopy); 13CNMR ((CD3)2SO, 125 MHz): d 26.3 (CH2), 34.7 (CH2), 44.1 (CH2), 46.0(CH2), 55.3 (CH2), 60.5 (CH), 71.2 (CH), 122.2 (C), 127.4 (CH), 128.8(C), 132.2 (C), 132.8 (CH), 147.8 (C), 150.2 (CH), 159.1 (C), 203.9 (C)ppm.		93%

Safety and Hazards

Pictogram(s)corrosionskullexclamation-markhealth-hazardenvironment Halofuginone CAS#: 55837-20-2
SignalDanger
GHS Hazard StatementsH300: Fatal if swallowed [Danger Acute toxicity, oral]
H301: Toxic if swallowed [Danger Acute toxicity, oral]
H310: Fatal in contact with skin [Danger Acute toxicity, dermal]
H315: Causes skin irritation [Warning Skin corrosion/irritation]
H317: May cause an allergic skin reaction [Warning Sensitization, Skin]
H318: Causes serious eye damage [Danger Serious eye damage/eye irritation]
H330: Fatal if inhaled [Danger Acute toxicity, inhalation]
H361: Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]
H400: Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
H410: Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]
Information may vary between notifications depending on impurities, additives, and other factors. 
Precautionary Statement CodesP201, P202, P260, P261, P262, P264, P270, P271, P272, P273, P280, P281, P284, P301+P310, P302+P350, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P314, P320, P321, P322, P330, P332+P313, P333+P313, P361, P362, P363, P391, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
For more detailed information, please visit ECHA C&L website

Other Data

TransportationNot dangerous goods
Under the room temperature and away from light
HS Code294200
StorageKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition. Recommended storage temperature:
-20°C 3 years
4°C 2 years
Shelf Life1 year
Market PriceUSD 2300/kg
Use Pattern
Halofuginone CAS#: 55837-20-2 is usually used as a pharmaceutical
angioplasty
atherectomy
atherosclerosis
bypass surgical procedure
drug-eluting stent
Halofuginone CAS#: 55837-20-2 is a less-toxic form of Febrifugine, which is isolated from the plant Dichroa febrifuga. Halofuginone inhibits prolyl-tRNA synthetase in an ATP-dependent manner with a Ki of 18.3 nM. Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity.

Halofuginone Lactate CAS#: 82186-71-8

By great_watson-int,
HALOFUGINONE-LACTATE-CAS-82186-71-8
IdentificationPhysical DataSpectra
Route of Synthesis (ROS)Safety and HazardsOther Data

Identification

英文名Halofuginone Lactate
IUPAC Name7-bromo-6-chloro-3-[3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;2-hydroxypropanoic acid
分子结构HALOFUGINONE-LACTATE-CAS-82186-71-8
CAS编号 82186-71-8
MDL NumberMFCD00144429
别名SCHEMBL2562822; CHEMBL1162014; C-22970; 7-bromo-6-chloro-3-(3-((2S,3R)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-one 2-hydroxypropanoate; Halocur; Stenorol; Tempostatin
分子式C19H23BrClN3O6
分子量504.8
InChIInChI=1S/C16H17BrClN3O3.C3H6O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14;1-2(4)3(5)6/h5-6,8,14-15,19,23H,1-4,7H2;2,4H,1H3,(H,5,6)/t14-,15+;/m0./s1
InChI KeyGATQERNJKZPJNX-NUNOUFIPSA-N
Canonical SMILESCC(C(=O)O)O.C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
Isomeric SMILESCC(C(=O)O)O.C1C[C@H](C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
Patent Information
No data available

Physical Data

AppearanceWhite or off-white powder
Melting Point>70°C dec.
Boiling Point595.8 °C at 760 mmHg
Flash Point314.1 °C
SolubilityDMSO : 9 mg/mL (21.70 mM; Need ultrasonic and warming)

Spectra

Halofuginone Lactate CAS#: 82186-71-8 IRIR of Halofuginon Lactate CAS 82186-71-8
Halofuginone Lactate CAS#: 82186-71-8 MSMS of Halofuginon Lactate CAS 82186-71-8

Route of Synthesis (ROS)

No data available

Safety and Hazards

Pictogram(s)corrosionskullexclamation-markhealth-hazardenvironment Halofuginone Lactate CAS#: 82186-71-8
SignalDanger
GHS Hazard StatementsH300: Fatal if swallowed [Danger Acute toxicity, oral]
H301: Toxic if swallowed [Danger Acute toxicity, oral]
H310: Fatal in contact with skin [Danger Acute toxicity, dermal]
H315: Causes skin irritation [Warning Skin corrosion/irritation]
H317: May cause an allergic skin reaction [Warning Sensitization, Skin]
H318: Causes serious eye damage [Danger Serious eye damage/eye irritation]
H330: Fatal if inhaled [Danger Acute toxicity, inhalation]
H361: Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]
H400: Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
H410: Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]
Information may vary between notifications depending on impurities, additives, and other factors. 
Precautionary Statement CodesP201, P202, P260, P261, P262, P264, P270, P271, P272, P273, P280, P281, P284, P301+P310, P302+P350, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P314, P320, P321, P322, P330, P332+P313, P333+P313, P361, P362, P363, P391, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationEnvironmentally hazardous substance, solid, n.o.s. ; Class 9; Packaging Group: III; UN Number: 3077
Under the room temperature and away from light
HS Code294200
StorageKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition. Recommended storage temperature:
-20°C 3 years
4°C 2 years
Shelf Life
Market PriceUSD 2300/kg
Use Pattern
Halofuginone Lactate CAS#: 82186-71-8 is used fvor the treatment of scleroderma, cancer, and restenosis.
Halofuginone Lactate CAS#: 82186-71-8 is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.
Halofuginone (RU-19110) is a less-toxic form of Febrifugine, which is isolated from the plant Dichroa febrifuga. Halofuginone inhibits prolyl-tRNA synthetase in an ATP-dependent manner with a Ki of 18.3 nM. Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity.
Halofuginone is a potent inhibitor of collagen a1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation. The profound antitumoral effect of halofuginone is attributed to its combined inhibition of the tumor stromal support, vascularization, invasiveness, and cell proliferation.

7-Bromo-6-chloro-4-quinazolinone CAS#: 17518-98-8

By great_watson-int,

Names & Identifiers
英文名 7-Bromo-6-chloro-4-quinazolinone
别名 7-Bromo-6-Chloro-4(3H)-Quinazo;7-Bromo-6-chloro-4-quinazolinone;7-Bromo-6-chloro-4(3H)-quinazolinone;7-BROMO-6-CHLORO-QUINAZOLINE-4(3H)-ONE;7-Bromo-6-chloro-4(1H)-quinazolinone;4(3H)-Quinazolinone, 7-broMo-6-chloro-;7-broMo-6-chloro-3,4-dihydroquinazolin-4-one;7-BroMo-6-chloro-4-quinaz…
CAS编号 17518-98-8
分子式 C8H4BrClN2O
分子量 259.49
EINECS
Other Registry Numbers
More Identifiers on PubChem IUPA Names, InChI, InChI Key, Canonical SMILES, etc.
7-Bromo-6-chloro-4-quinazolinone CAS#: 17518-98-8

Chemical & Physical Properties
Melting point  >300°C
Storage  Refrigerator

Safety & Hazards(Codes & Phrases)
More Safety & Hazards From PubChem Signal, GHS Hazard Statements, Precautionary Statement Codes, etc.

Literature
Literature on PubChem Synthesis References, Metabolite References, etc.

Patents
Patents on PubChem Related Patents Of This Product

Transportation, Storage & Usage
Transportation No Information
Storage No Information
Usage No Information

Spectral Properties
No Information

Halofuginone hydrobromide CAS#: 64924-67-0

By great_watson-int,
IdentificationPhysical DataSpectra
Route of Synthesis (ROS)Safety and HazardsOther Data

Identification

英文名Halofuginone hydrobromide
IUPAC Name7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide; trans-(±)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone monohydrobromide
分子结构
CAS编号 64924-67-0
EINECS Number241-422-7
MDL NumberMFCD23843776
别名7-bromo-6-chlorofebrifugine
Hbr; halofuginone; halofunginone; Stenorol; 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one HBr; Tempostatin; RU 19110;
分子式C16H18Br2ClN3O3
分子量495.60
InChIInChI=1S/C16H17BrClN3O3.BrH/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14;/h5-6,8,14-15,19,23H,1-4,7H2;1H
InChI KeySJUWEPZBTXEUMU-LDXVYITESA-N
Canonical SMILESC1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O.Br
Patent Information
No data available

Physical Data

AppearanceWhite or off-white powder
Melting Point>217°C dec.
Flash Point>70°C dec.
SolubilityDMSO : 9 mg/mL (21.70 mM; Need ultrasonic and warming)

Spectra

Halofuginone hydrobromide CAS#: 64924-67-0 HNMRHalofuginone hydrobromide CAS#: 64924-67-0 HNMR

Route of Synthesis (ROS)

No data available

Safety and Hazards

Pictogram(s)exclamation-mark
SignalWarning
GHS Hazard StatementsH302 (92%): Harmful if swallowed [Warning Acute toxicity, oral]
Information may vary between notifications depending on impurities, additives, and other factors.
Precautionary Statement CodesP264, P270, P301+P312, P330, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
For more detailed information, please visit ECHA C&L website
Source: European Chemicals Agency (ECHA)
License Note: Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: “Source: European Chemicals Agency, http://echa.europa.eu/”. Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.
License URL: https://echa.europa.eu/web/guest/legal-notice
Record Name: 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide
URL: https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/228694
Description: The information provided here is aggregated from the “Notified classification and labelling” from ECHA’s C&L Inventory. Read more: https://echa.europa.eu/information-on-chemicals/cl-inventory-database

Other Data

TransportationNot dangerous goods
Under the room temperature and away from light
HS Code294200
StorageKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.
Shelf Life-20°C 3 years
4°C 2 years
Market PriceUSD 2300/kg
Use Pattern
Halofuginone hydrobromide CAS#: 64924-67-0 is a specific collagen Type I inhibitor that antagonize or inhibit the development of new blood vessels, hence can prevent intimal hyperplasia at a vascular anastomosis. It is used in the treatment or prevention of coccidiosis in both humans and animals.